In focus
Latest feed
EyePoint's Rollercoaster Week: A Glimmer of Hope Amidst Trial Setbacks and Downgrades
Why Did Regenxbio (RGNX) Shares Take Such a Steep Dive After Hours? Unpacking the Gene Therapy News
Regeneron's Remarkable Resurgence: Charting the Course of a Biotech Comeback
Dame Judi Dench's Vision Struggles: Understanding Macular Degeneration
